Caplin Point Subsidiary Receives US FDA OAI Status for Gummidipoondi Facility
Caplin Point Laboratories Ltd 路 Others (Uncategorized) 路 17 Nov 2026, 7:31 pm
Caplin Point Subsidiary Receives US FDA OAI Status for Gummidipoondi Facility The US FDA classified the inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility at Gummidipoondi as Official Action Indicated (OAI) following an unannounced audit conducted between 13th Aug'26 and 21st Aug'26, which concluded with 10 procedural observations. Caplin Point Laboratories stated that the facility continues manufacturing and product supplies with no immediate material impact on financials or operations. The company is actively working with the regulator to implement corrective and preventive actions to address the observations.
Original exchange filing (PDF)
More announcements from Caplin Point Laboratories Ltd
- Audio Recording of Earnings call for the Quarter and half year ended September 30, 2026 路 13 Nov 2026
- Investor Presentation for the Earnings Call for the Quarter and half year ended September 30, 2026 路 12 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 12 Nov 2026
- Board Meeting Outcome for Meeting Held on November 12, 2026 路 12 Nov 2026
- Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 12 Nov 2026
- Analyst / investor Call for the quarter and half ended September 30, 2026 路 12 Nov 2026
- CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 12 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 12 Nov 2026
